Shares of Cerenome (CNSY) jumped 10.5% to $2.10 on Monday after its diagnostics unit, CNSide Diagnostics, announced that Blue Cross Blue Shield of Michigan will reimburse its cerebrospinal-fluid test used to detect central nervous system tumor cells — a deal effective September 1 that the company says expands contracted coverage to roughly 158 million commercial and Medicare Advantage lives nationwide. Cerenome Clears a Major Insurance Hurdle for Its Brain Cancer Test — But Is a $15 Million Company Ready to Cash In?
Shares of Cerenome (CNSY) spiked as much as 10.5% to $2.10 Monday after its diagnostics subsidiary announced an in-network deal with Blue Cross Blue Shield of Michigan, the latest in a string of insurer agreements that now cover an estimated 158 million Americans. For a micro-cap company with a market value hovering around just $15 million, the question is whether payer wins can translate into meaningful revenue before cash runs out.
• Insurance Coverage Doubled in Six Months, Hitting the Company's Own Target. As recently as April, Cerenome's brain-fluid cancer test covered only about 75 million lives , after adding Highmark to deals with UnitedHealthcare and Humana. The company's stated 2026 goal was to reach 150 million covered lives.
BCBSM alone serves roughly 5 million members , but combined with a Health Care Service Corporation deal signed in August, total contracted coverage now stands at approximately 158 million. Hitting that milestone removes a key adoption barrier: doctors are far more likely to order a diagnostic test when they know the patient's insurer will pay for it.
• The Test Exists in a Tiny, Real Market — Over 11,000 Tests Already Run. More than 11,000 tests have been performed at over 120 U.S. cancer institutions. The test analyzes spinal fluid to detect cancer cells that have spread to the brain and spinal cord — a devastating condition with few diagnostic options. Conference data suggest the test could reduce monthly treatment costs for these patients by up to 47%. That health-economics argument is what persuades insurers, but the installed base is still small relative to the new coverage footprint.
• A Fresh $20 Million Credit Line Buys Time, but the Clock Is Ticking. On September 10, Cerenome secured a senior financing facility of up to $20 million from 3i, LP, with repayments tied to future royalties.
Management says cash runway now extends "well into 2028." But full-year 2025 revenue was just $5.2 million — down 10.5% from the prior year — while losses ballooned to $22.4 million.
R&D spending recently hit 297.6% of revenue , underscoring how far costs outstrip sales.
• The Stock Sits Near Its All-Time Low Despite a Parade of Good News. Over the past year, shares have ranged from $1.90 to $23.43 — today's price is pennies above the floor. A 1-for-25 reverse stock split took effect in April to keep the stock listed on Nasdaq.
Four analysts rate it a "Strong Buy" with an average target of $32.50 , but that yawning gap between Wall Street optimism and market reality reflects deep skepticism that a company burning cash this fast can commercialize before needing more dilutive capital.